Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Non-Invasive Monitoring of Stromal Biophysics with Targeted Depletion of Hyaluronan in Pancreatic Ductal Adenocarcinoma.

Maloney E, DuFort CC, Provenzano PP, Farr N, Carlson MA, Vohra R, Park J, Hingorani SR, Lee D.

Cancers (Basel). 2019 Jun 4;11(6). pii: E772. doi: 10.3390/cancers11060772.

2.

Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma.

Stromnes IM, Burrack AL, Hulbert A, Bonson P, Black C, Brockenbrough JS, Raynor JF, Spartz EJ, Pierce RH, Greenberg PD, Hingorani SR.

Cancer Immunol Res. 2019 Jun;7(6):977-989. doi: 10.1158/2326-6066.CIR-18-0448. Epub 2019 Apr 26.

PMID:
31028033
3.

A BODIPY-Based Donor/Donor-Acceptor System: Towards Highly Efficient Long-Wavelength-Excitable Near-IR Polymer Dots with Narrow and Strong Absorption Features.

Chen L, Chen D, Jiang Y, Zhang J, Yu J, DuFort CC, Hingorani SR, Zhang X, Wu C, Chiu DT.

Angew Chem Int Ed Engl. 2019 May 20;58(21):7008-7012. doi: 10.1002/anie.201902077. Epub 2019 Apr 12.

PMID:
30912228
4.

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.

Ramanathan RK, McDonough SL, Philip PA, Hingorani SR, Lacy J, Kortmansky JS, Thumar J, Chiorean EG, Shields AF, Behl D, Mehan PT, Gaur R, Seery T, Guthrie KA, Hochster HS.

J Clin Oncol. 2019 May 1;37(13):1062-1069. doi: 10.1200/JCO.18.01295. Epub 2019 Feb 28.

PMID:
30817250
5.

Fibroblasts in Pancreatic Ductal Adenocarcinoma: Biological Mechanisms and Therapeutic Targets.

Whittle MC, Hingorani SR.

Gastroenterology. 2019 May;156(7):2085-2096. doi: 10.1053/j.gastro.2018.12.044. Epub 2019 Feb 2. Review.

PMID:
30721663
6.

COQ2 nephropathy: a treatable cause of nephrotic syndrome in children.

Starr MC, Chang IJ, Finn LS, Sun A, Larson AA, Goebel J, Hanevold C, Thies J, Van Hove JLK, Hingorani SR, Lam C.

Pediatr Nephrol. 2018 Jul;33(7):1257-1261. doi: 10.1007/s00467-018-3937-z. Epub 2018 Apr 10.

7.

Mesenchymal Cell Plasticity and Perfidy in Epithelial Malignancy.

Puré E, Hingorani SR.

Trends Cancer. 2018 Apr;4(4):273-277. doi: 10.1016/j.trecan.2018.02.007. Epub 2018 Mar 11. Review.

PMID:
29606311
8.

Prematurity and future kidney health: the growing risk of chronic kidney disease.

Starr MC, Hingorani SR.

Curr Opin Pediatr. 2018 Apr;30(2):228-235. doi: 10.1097/MOP.0000000000000607. Review.

9.

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.

Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa S, Pu J, Aldrich C, Hendifar AE.

J Clin Oncol. 2018 Feb 1;36(4):359-366. doi: 10.1200/JCO.2017.74.9564. Epub 2017 Dec 12.

PMID:
29232172
10.

Understanding Disease Biology and Informing the Management of Pancreas Cancer With Preclinical Model Systems.

Whittle MC, Hingorani SR.

Cancer J. 2017 Nov/Dec;23(6):326-332. doi: 10.1097/PPO.0000000000000289. Review.

11.

T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma.

Stromnes IM, Hulbert A, Pierce RH, Greenberg PD, Hingorani SR.

Cancer Immunol Res. 2017 Nov;5(11):978-991. doi: 10.1158/2326-6066.CIR-16-0322. Epub 2017 Oct 24.

12.

Fluid: Too Much or Too Little-Transplant Mortality May Hang in the Balance.

Hingorani SR.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2020-2022. doi: 10.1016/j.bbmt.2017.10.032. Epub 2017 Oct 20. No abstract available.

13.

Impact of processing methods on urinary biomarkers analysis in neonates.

Starr MC, Askenazi DJ, Goldstein SL, MacDonald JW, Bammler TK, Afsharinejad Z, D Brophy P, Juul SE, Mayock DE, Hingorani SR.

Pediatr Nephrol. 2018 Jan;33(1):181-186. doi: 10.1007/s00467-017-3779-0. Epub 2017 Aug 19.

14.

Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer.

Farr N, Wang YN, D'Andrea S, Starr F, Partanen A, Gravelle KM, McCune JS, Risler LJ, Whang SG, Chang A, Hingorani SR, Lee D, Hwang JH.

Int J Hyperthermia. 2018 May;34(3):284-291. doi: 10.1080/02656736.2017.1336675. Epub 2017 Jul 17.

15.

Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20).

Wong KM, Horton KJ, Coveler AL, Hingorani SR, Harris WP.

Curr Oncol Rep. 2017 Jul;19(7):47. doi: 10.1007/s11912-017-0608-3. Review.

PMID:
28589527
16.

Photostable Ratiometric Pdot Probe for in Vitro and in Vivo Imaging of Hypochlorous Acid.

Wu L, Wu IC, DuFort CC, Carlson MA, Wu X, Chen L, Kuo CT, Qin Y, Yu J, Hingorani SR, Chiu DT.

J Am Chem Soc. 2017 May 24;139(20):6911-6918. doi: 10.1021/jacs.7b01545. Epub 2017 May 11.

17.

Runx3 and Cell Fate Decisions in Pancreas Cancer.

Whittle MC, Hingorani SR.

Adv Exp Med Biol. 2017;962:333-352. doi: 10.1007/978-981-10-3233-2_21. Review.

PMID:
28299667
18.

Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer.

Zhong Y, Macgregor-Das A, Saunders T, Whittle MC, Makohon-Moore A, Kohutek ZA, Poling J, Herbst BT, Javier BM, Cope L, Leach SD, Hingorani SR, Iacobuzio-Donahue CA.

Clin Cancer Res. 2017 Mar 15;23(6):1607-1620. doi: 10.1158/1078-0432.CCR-15-1615. Epub 2016 Sep 16.

19.

RUNX3 defines disease behavior in pancreatic ductal adenocarcinoma.

Whittle MC, Hingorani SR.

Mol Cell Oncol. 2015 Jul 29;3(2):e1076588. doi: 10.1080/23723556.2015.1076588. eCollection 2016 Mar.

20.

Tension and Transformation in Pancreas Cancer: Can Phenotype Break Free from the Chrysalis of Genotype?

DuFort CC, Hingorani SR.

Cancer Cell. 2016 Jun 13;29(6):780-782. doi: 10.1016/j.ccell.2016.05.015.

21.

Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase.

DuFort CC, DelGiorno KE, Carlson MA, Osgood RJ, Zhao C, Huang Z, Thompson CB, Connor RJ, Thanos CD, Scott Brockenbrough J, Provenzano PP, Frost GI, Michael Shepard H, Hingorani SR.

Biophys J. 2016 May 10;110(9):2106-19. doi: 10.1016/j.bpj.2016.03.040.

22.

Optical painting and fluorescence activated sorting of single adherent cells labelled with photoswitchable Pdots.

Kuo CT, Thompson AM, Gallina ME, Ye F, Johnson ES, Sun W, Zhao M, Yu J, Wu IC, Fujimoto B, DuFort CC, Carlson MA, Hingorani SR, Paguirigan AL, Radich JP, Chiu DT.

Nat Commun. 2016 Apr 27;7:11468. doi: 10.1038/ncomms11468.

23.

Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma.

DuFort CC, DelGiorno KE, Hingorani SR.

Gastroenterology. 2016 Jun;150(7):1545-1557.e2. doi: 10.1053/j.gastro.2016.03.040. Epub 2016 Apr 9. Review.

24.

Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.

Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin SA, Gladkov OA, Holcombe RF, Korn R, Raghunand N, Dychter S, Jiang P, Shepard HM, Devoe CE.

Clin Cancer Res. 2016 Jun 15;22(12):2848-54. doi: 10.1158/1078-0432.CCR-15-2010. Epub 2016 Jan 26.

25.

Complete Remission in the Nephrotic Syndrome Study Network.

Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson PJ, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, Nachman PH, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova O, Hodgin JB, Johnstone DB, Adler SG, Avila-Casado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, Mokrzycki MH, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):81-9. doi: 10.2215/CJN.02560315. Epub 2015 Dec 10.

26.

T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.

Stromnes IM, Schmitt TM, Hulbert A, Brockenbrough JS, Nguyen H, Cuevas C, Dotson AM, Tan X, Hotes JL, Greenberg PD, Hingorani SR.

Cancer Cell. 2015 Nov 9;28(5):638-652. doi: 10.1016/j.ccell.2015.09.022. Epub 2015 Oct 29.

27.

Disconnect between EMT and metastasis in pancreas cancer.

Whittle MC, Hingorani SR.

Oncotarget. 2015 Oct 13;6(31):30445-6. doi: 10.18632/oncotarget.5720. No abstract available.

28.

Intercepting Cancer Communiques: Exosomes as Heralds of Malignancy.

Hingorani SR.

Cancer Cell. 2015 Aug 10;28(2):151-3. doi: 10.1016/j.ccell.2015.07.015.

29.

Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer.

Li T, Wang YN, Khokhlova TD, D'Andrea S, Starr F, Chen H, McCune JS, Risler LJ, Mashadi-Hossein A, Hingorani SR, Chang A, Hwang JH.

Cancer Res. 2015 Sep 15;75(18):3738-46. doi: 10.1158/0008-5472.CAN-15-0296. Epub 2015 Jul 27. Erratum in: Cancer Res. 2017 May 15;77(10 ):2771.

30.

RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma.

Whittle MC, Izeradjene K, Rani PG, Feng L, Carlson MA, DelGiorno KE, Wood LD, Goggins M, Hruban RH, Chang AE, Calses P, Thorsen SM, Hingorani SR.

Cell. 2015 Jun 4;161(6):1345-60. doi: 10.1016/j.cell.2015.04.048. Epub 2015 May 21.

31.

Markers of coagulation activation and acute kidney injury in patients after hematopoietic cell transplantation.

Hingorani SR, Seidel K, Pao E, Lawler R, McDonald GB.

Bone Marrow Transplant. 2015 May;50(5):715-20. doi: 10.1038/bmt.2015.2. Epub 2015 Feb 9.

32.

Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer.

Mirus JE, Zhang Y, Li CI, Lokshin AE, Prentice RL, Hingorani SR, Lampe PD.

Clin Cancer Res. 2015 Apr 1;21(7):1764-71. doi: 10.1158/1078-0432.CCR-13-3474. Epub 2015 Jan 14.

33.

Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Tabernero J, Chiorean EG, Infante JR, Hingorani SR, Ganju V, Weekes C, Scheithauer W, Ramanathan RK, Goldstein D, Penenberg DN, Romano A, Ferrara S, Von Hoff DD.

Oncologist. 2015 Feb;20(2):143-50. doi: 10.1634/theoncologist.2014-0394. Epub 2015 Jan 12.

34.

Spatiotemporal proteomic analyses during pancreas cancer progression identifies serine/threonine stress kinase 4 (STK4) as a novel candidate biomarker for early stage disease.

Mirus JE, Zhang Y, Hollingsworth MA, Solan JL, Lampe PD, Hingorani SR.

Mol Cell Proteomics. 2014 Dec;13(12):3484-96. doi: 10.1074/mcp.M113.036517. Epub 2014 Sep 15.

35.

Molecular pathways: myeloid complicity in cancer.

Stromnes IM, Greenberg PD, Hingorani SR.

Clin Cancer Res. 2014 Oct 15;20(20):5157-70. doi: 10.1158/1078-0432.CCR-13-0866. Epub 2014 Jul 21. Review.

36.

Response to Chauhan et Al.: interstitial pressure and vascular collapse in pancreas cancer-fluids and solids, measurement and meaning.

DelGiorno KE, Carlson MA, Osgood R, Provenzano PP, Brockenbough JS, Thompson CB, Shepard HM, Frost GI, Potter JD, Hingorani SR.

Cancer Cell. 2014 Jul 14;26(1):16-7. doi: 10.1016/j.ccr.2014.06.004. No abstract available.

37.

Cellular and molecular conspirators in pancreas cancer.

Hingorani SR.

Carcinogenesis. 2014 Jul;35(7):1435. doi: 10.1093/carcin/bgu138. No abstract available.

PMID:
24987024
38.

Stromal reengineering to treat pancreas cancer.

Stromnes IM, DelGiorno KE, Greenberg PD, Hingorani SR.

Carcinogenesis. 2014 Jul;35(7):1451-60. doi: 10.1093/carcin/bgu115. Epub 2014 Jun 7. Review.

39.

Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.

Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, Greenberg PD, Hingorani SR.

Gut. 2014 Nov;63(11):1769-81. doi: 10.1136/gutjnl-2013-306271. Epub 2014 Feb 20.

40.

Transient renal enlargement in pediatric hematopoietic cell transplant recipients.

Chapman T, Bodmer N, Benkeser DC, Hingorani SR, Parisi MT.

Pediatr Transplant. 2014 May;18(3):288-93. doi: 10.1111/petr.12225. Epub 2014 Jan 20.

PMID:
24438462
41.

Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Stromnes IM, Schmitt TM, Chapuis AG, Hingorani SR, Greenberg PD.

Immunol Rev. 2014 Jan;257(1):145-64. doi: 10.1111/imr.12141. Review.

42.

Nephrolithiasis in pediatric hematopoietic cell transplantation with up to 40 years of follow-up.

Hoffmeister PA, Storer BE, Baker KS, Hingorani SR.

Pediatr Blood Cancer. 2014 Mar;61(3):417-23. doi: 10.1002/pbc.24760. Epub 2013 Sep 9.

PMID:
24038785
43.

Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer.

Husain K, Centeno BA, Chen DT, Hingorani SR, Sebti SM, Malafa MP.

Cancer Prev Res (Phila). 2013 Oct;6(10):1074-83. doi: 10.1158/1940-6207.CAPR-13-0157. Epub 2013 Aug 20.

44.

Acute kidney injury and its association with in-hospital mortality among children with acute infections.

Imani PD, Odiit A, Hingorani SR, Weiss NS, Eddy AA.

Pediatr Nephrol. 2013 Nov;28(11):2199-206. doi: 10.1007/s00467-013-2544-2. Epub 2013 Jul 20.

PMID:
23872929
45.

Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer.

Spivak-Kroizman TR, Hostetter G, Posner R, Aziz M, Hu C, Demeure MJ, Von Hoff D, Hingorani SR, Palculict TB, Izzo J, Kiriakova GM, Abdelmelek M, Bartholomeusz G, James BP, Powis G.

Cancer Res. 2013 Jun 1;73(11):3235-47. doi: 10.1158/0008-5472.CAN-11-1433. Epub 2013 Apr 30.

46.

Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach.

Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PX, Barisoni L, Sampson MG, Kopp JB, Lemley KV, Nelson PJ, Lienczewski CC, Adler SG, Appel GB, Cattran DC, Choi MJ, Contreras G, Dell KM, Fervenza FC, Gibson KL, Greenbaum LA, Hernandez JD, Hewitt SM, Hingorani SR, Hladunewich M, Hogan MC, Hogan SL, Kaskel FJ, Lieske JC, Meyers KE, Nachman PH, Nast CC, Neu AM, Reich HN, Sedor JR, Sethna CB, Trachtman H, Tuttle KR, Zhdanova O, Zilleruelo GE, Kretzler M.

Kidney Int. 2013 Apr;83(4):749-56. doi: 10.1038/ki.2012.428. Epub 2013 Jan 16.

47.

Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E δ-tocotrienol.

Husain K, Centeno BA, Chen DT, Fulp WJ, Perez M, Zhang Lee G, Luetteke N, Hingorani SR, Sebti SM, Malafa MP.

Carcinogenesis. 2013 Apr;34(4):858-63. doi: 10.1093/carcin/bgt002. Epub 2013 Jan 9.

48.

Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer.

Provenzano PP, Hingorani SR.

Br J Cancer. 2013 Jan 15;108(1):1-8. doi: 10.1038/bjc.2012.569. Epub 2013 Jan 8. Review.

49.

Pancreas cancer meets the thunder god.

Hingorani SR, Potter JD.

Sci Transl Med. 2012 Oct 17;4(156):156ps21. doi: 10.1126/scitranslmed.3004956.

PMID:
23076355
50.

Changes in connexin43 expression and localization during pancreatic cancer progression.

Solan JL, Hingorani SR, Lampe PD.

J Membr Biol. 2012 Jun;245(5-6):255-62. doi: 10.1007/s00232-012-9446-2. Epub 2012 Jun 23.

Supplemental Content

Loading ...
Support Center